

Systems-Driven Technologies and Strategies



- Technologies
 - 3rd generation DNA sequencing (\$100 genome)
 - Targeted proteomics (blood biomarkers)—SRM Atlas
 - Peptide protein-capture agents (replace antibodies as diagnostics and drugs)
 - Single-cell analyses (deciphering biological complexities)
- Strategies
 - Family genome sequencing (identify disease genes and compare 1000s of genomes)
 - Animal model disease dynamics (identify earliest disease-perturbed networks)
 - **Blood biomarker discovery** ((cancer, preterm birth, PTSD, liver disease)
 - Organ-specific blood proteins for wellness and disease
 - Dense, dynamic, personal data clouds to analyze wellness and disease
 - Billions of natural synthetic products as drugs
 - Translating data to disease-perturbed networks and their analysis to identify drug target candidates
 - Use disease-perturbed networks to identify drug target candidates
 - Blood is a window into the dynamics of human biology and disease (separate/analyze molecules of blood, vesicles, cells)
 Institute for Systems Biology


A Systems View of Big Data:




Dealing with Biological Complexity of Complex Systems

- Global analyses of all components—DNA, RNA protein, etc.
- Dynamics of systems (networks)—temporal and spatial
- · Integration of different data types from the system
- Use of theoretical conceptual approaches for new insights into biology: dynamical systems theory and thermodynamical phase transitions in biology
- Development of platforms for systems-driven technologies and strategies is key (family genome sequencing)
- Large data sets reflect two types of noise—biological and technical








3rd Generation DNA Sequencing


- Ease of sample preparation
- Single molecule analysis
- Nanopore sequencer
- Electronic detection
- Detect 16 epigenetic modifications of DNA
- In principle could sequence RNA as well as DNA
- Enormous parallelization and minaturization
- Whole human genome sequence in 15 minutes for less than \$100








Prion-Induce Neurodegeneration: An Animal Model for Studying the Dynamics of a Disease


Dawhee Huang, Inyoul Lee, George Carlson, Lee Hood

















Systems Approach to Distinguishing Benign from Malignant Lung Cancer Nodules (with Integrated Diagnostics)



- 371 SRM assays for lung cancer tissue/190 detectable in the blood
 - Differentially secreted (normal vs. neoplastic)
 - Differentially shed from cell surface (normal vs. neoplastic)
 - Candidates captured from the literature
- Discovery samples—analyze all 190 detectable proteins
 - 72 cancer vs. 72 benign-from four sites
- Discovery algorithm for "cooperative" proteins
 - Select the 32 (out of 190) best proteins for distinguishing nodules
 - A million random panels of 10 of 32 best proteins were scored
 - Identified 13 proteins that were highly "cooperative"—generally in most effective panels
- Validation study—13-protein panel—identifies 36% of benign nodules
 - 52 cancer vs. 52 benign-from 4 old sites plus 1 new site
 - Identifies 36% of the benign lung nodules
- Integrated Diagnostics commercialize the panel of 13 blood proteins in Q4 2013
- Integrated Diagnostics develops a two-protein blood panel that identifies more than 50% of the benign lung nodules 2016

Bold Blue indicates systems-driven approaches. X. Li et.al. Science Translation Medicine: 5, 207, 2013



Systems Driven Blood Targeted Human Blood Protein Biomarkers



Validated

- Distinguish benign and neoplastic lung nodules—two blood proteins can identify with more than 95% specificity more than 50% benign nodules—saving US healthcare more that \$4.5 billion/year
- Preterm birth —two blood proteins can distinguish at 19 weeks mothers destined to have preterm birth from those with normal births (Sera Prognostics in Salt Lake City)—in time for actionable therapy


Discovery

- Post traumatic stress disorder (PTSD)—2 blood proteins that allow one to distinguish from plasma 50 normal Afghanistan soldiers and 50 PTSD Afghanistan soldiers (ISB)
- Glioblastoma—4 blood proteins distinguish normal from patients with glioblastoma
- Liver disease—4 proteins identify AIDS-induced fibrosis and titute for multiple proteins identify liver toxicity—acetaminophin policies


Single Cell Analyses Following the Development of iPS Cells to Cardiomyocytes

Kalli Trachana, Rhishi Bargaje, Martin Shelton Sui Huang, Lee Hood











Contemporary **P4 Medicine** Medicine **Proactive** Reactive Individual **Population** Wellness & disease Only disease Personalized data Averaged patient clouds populations Personalized data clouds **Averaged patient** for clinical trials populations for clinical (N=1 experiments) trials Patient activated social Institute for Systems Biology networks








The 108 Person Wellness Project 2014 (Pioneers)

Principal Investigators: Lee Hood and Nathan Price Using dense, dynamic, personal data clouds for wellness IRB approved study














Vitamin D Deficiency: Arising from Both Genetics and Environment—N=1 Experiments Key

- Vitamin D 90/108 Pioneers were low
- Six genetic variants from 3 genes block Vitamin D absorption
- Those with multiple blocking variants and presumably unknown variants, need mega-doses of Vitamin D
- Unknown blocking factors


Risks associated with low Vitamin D

- Ricketts

 improper bone mineralization
- Increased risk of death from cardiovascular disease
- Cognitive impairment in older adults– Alzheimer's
- Severe asthma in children
- Cancer




Pioneer with 3 years of Neuralgia and Facial Bell's Palsy Almost no blood vitamin B12 Actionable Possibility: Intramuscular injections of B12 and reversed completely in 3 months
































Association of FGF-21 and 'Cardiometabolic' Community




We identified a significant negative relationship between the protein Fibroblast Growth Factor 21 and levels of triglycerides, HOMA-IR, and c-peptide.


FGF21 is a recently discovered metabolic regulator. Obese diabetic patients treated with an FGF21 analog showed improvements (decreases) in triglycerides and LDL cholesterol. This analog is in clinical trials by the pharmaceutical company Eli Lilly (A Study of LY2405319 in Participants With Type 2 Diabetes).





We can determine your genetic risk for at least 60 diseases.

















Early Wellness to Disease Transitions: Arivale

Disease	Diagnosed	Pre-diagnosis blood draws*	Post diagnosis blood draws*
Diverticulosis	February 2017	1	0
Prostate cancer	June 2016	5	2
Melanoma	January 2017	3	0
Aortic aneurysm (fatal)	September 2016	3	-
Hypertension	February 2017	7	0
Hypertension	March 2017	5	0
Eosinophilic esophagitis	February 2016	1	3
Melanoma	September 2016	1	0
Colon Cancer	September 2016	2	0
Oral cancer	June 2016	1	1
Squamous cell carcinoma	December 2016	2	0
Hemorrhagic stroke	March 2017	2	0


^{*} Approximately 6 months between draws




Pioneer Diagnosed with Stage 4 Pancreatic Cancer

- Female, 57 years old, Caucasian, non-Hispanic
- Diagnosed January 2017
- Four historical blood draws and two microbiome samples available

Can we find anything detectable in plasma that could have indicated the cancer was present?





Early Disease Reversal:Preventive Medicine of the 21st Century



 In following 10,000 or more patients over an extended time period, we will start to see wellness

to **early disease transitions** for all common diseases (as measured by blood analytes).

- Use systems approaches to develop blood biomarkers for early transitions for each disease and disease-perturbed network biology for therapies to reverse the disease at the earliest transition.
- Thus individuals will have diseases reversed before the diseases manifest themselves a disease phenotype—preventive medicine of the 21st century

Systems Biology


State Transition: Aging




Quantitative Blood Metrics for Wellness



- Two approaches
 - Follow individuals from wellness to greater wellness and follow what changes in the data clouds. Promising possibilities with blood proteins and metabolites.
 - Follow individuals as they age (variability in range of omic measurements increases significantly)
- We believe that we can do this for both physiological and psychological wellness
- · Physiological vs. chronological age
- These approaches will provide powerful metrics against which wellness improvements for individuals can be assessed.





	Hospitals	50
	198	
SB & Providence	Physicians	7500
St. Joseph Health	RNs	36,000
Affiliation	Unique	
Maska, California, Oregon, Montana, Washington,	patients served each year	5 million
lew Mexico, Texas	Total Assets	\$20 billion


Translational Pillars


- 1. Scientific wellness
- 2. Alzheimer's
- 3. Type 2 diabetes
- 4. Glioblastoma
- 5. Wellness for breast cancer survivors
- 6. Liver disease
- 7. Multiple sclerosis

Strategies

Systems-driven technologies and strategies
Dense, dynamic, personal data clouds







Bringing P4 medicine and scientific wellness to the healthcare system Precision medicine—employ dense, dynamic data clouds for each individual to allow one to explore interactions between genetics and environment Optimize wellness through actionable possibilities Reverse disease at its earliest transition point: Prevention of the 21st century The Future Scientific Wellness: A lifetime journey of Healthcare Healthcare costs dramatically reduced Creation of a Scientific Wellness Industry Transformation of biotech, pharma, diagnostic, nutrition industries **Democratization of healthcare**

ISB Hundred Person Wellness Project: Team



Special thanks to our funders: Robert Wood Johnson Foundation, M.J. Murdock Charitable Trust, Maveron and ISB

Project Leadership

- Leroy Hood, MD, PhD
- Nathan Price, PhD
- Clayton Lewis
- Sean Bell, Business Director

Participant Engagement

- · Jennifer Lovejoy, PhD, VP Clinical Affairs
- · Sandi Kaplan, Wellness Coach
- · Craig Keebler, MD, Study Physician

Data Analytics

- Nathan Price, PhD Analytics Lead Gustavo Glusman, PhD, Genomics
- · Andrew Magis, PhD, Multi-omics
- John Earls, Data integration

Project Management

- · Kristin Brogaard, PhD Project Manager
- Sara Mecca, Project Assistant
- · Mary Brunkow, PhD, Project Coordinator

Communications


- · Gretchen Sorenson, Consultant
- Hsiao-Ching Chou, Comm. Director


Medical Advisory Board


- · Robert Green, MD
- · Jane Guiltinan, ND
- Michael Raff, MD
- Sarah Speck, MD
- Gil Omenn MD













Six Instruments Developed by Hood Laboratory



- Protein Sequencer Caltech—Applied Biosystems
- 2 Protein Synthesizer Caltech—Applied Biosystems
- 3 DNA Sequencer
 Caltech—Applied Biosystems
 DNA Synthesizer
 Caltech—Applied Biosystems
- 4 Ink-jet oligonucleotide DNA synthesizer
 MBT/UW—Rosetta then Agilent
- 5 Nanostring nCounter ISB—Nanostring


*Hood startup companies



It will be important to measure complex phenotypes in the future—to assay the contributions of multiple systems to wellness (and disease)

- Heart rate variability
- Computer key board strokes
- Facial recognition analyses
- EEG—longitudinal analyses of brain waves
- EKG—longitudinal analyses of heart waves
- Whole body imaging—omics blood analyses will eliminate signal to noise problems







Organ-Specific Blood Proteins: Blood As a Window Into the Dynamics of Human Biology and Disease

Shizen Qin, Yong Zhou, Lee Hood







Organ-Specific Transcripts and Proteins




- Identified organ-specific (organ-enriched) transcript lists for 19 major human organs (1600 transcripts from more than 20 different protein and transcriptome databases)
- Developed refined SRM assays to measure OSPs in the blood-745 proteins/1,421 peptides, and identified 211 proteins from 19 organs
- Why organ-specific proteins are missing in blood—two reasons—low levels or are not in blood
- Used to study liver fibrosis, liver toxicity and Lyme Disease (5 organs affected)
- Our goal is to develop a single blood-based test to monitor about 50 major organs with 10-20 organspecific proteins for each organ as a wellness assay
- Blood as a window into the dynamics of human biology and disease

Peptide Protein-Capture Agents will Replace Antibodies

Jim Heath, Caltech Indi Molecular







Peptide Protein Capture Agents-Features


- Stable—send to Africa in an envelop
- Sensitive—each monomer a log increase in sensitivity
- Digital—synthesize unlimited quantities
- Minimum cross reactivity--can be precisely directed at epitopes—hence avoids much of the cross-reactivities that plague antibodies
- Can be adapted to large-scale production through automation—easy to produce
- Functions
 - In vitro diagnosis
 - In vivo diagnosis
 - Therapeutic reagents—possibly lacking cross reactivities
- Prediction—will replace monoclonal antibodies with 10-15 years











Arivale Management




- Clayton Lewis CEO
- Sean Bell CBO
- Jennifer Lovejoy CTSO
- Michael Kaplan Director, Clinical Science
- Andrew Magis Sr. Bioinformatics Scientist
- Isabelle Lucas-Beckett Translational Geneticist
- Sandi Kaplan Sr. Director, Coaching
- Ashley Wells Director, Product Development



Democratization of Scientific Wellness

- Todays major limitation for scientific wellness is the cost of the assays
- In 10 years, the annual cost of scientific wellness will decline from \$5,000 to less than \$100
- Avatars and apps will leverage wellness coaches and digital devices are emerging for measurements of simple and complex phenotypes
- Scientific wellness will be covered by health insurance and government payers.
- This coverage will allow the poor, middleclass and rich to be covered for scientific wellness



Scientific Wellness Will Strikingly Reduce Healthcare Costs



- · Optimize wellness—and thus avoid many initial disease transitions
- Identify diseases in newly enrolled pioneers and reverse them early hemachromatosis, diabetes, cardiovascular disease, etc.
- Identify and reverse earliest disease transitions before they manifest as disease phenotype—preventive medicine of 21st century
- Increasing inexpensive digital devices measure simple and complex phenotypes—useful in reducing dimensionality of assays
- Increasing knowledge of wellness will allow us to focus and target measurements—again reducing dimensionality from billions to say 5,000
- Moore's law decline in cost of wellness assays—with miniaturization, parallelization, integration, automation, etc.
- Follow closely potential early disease transitions in individuals at high risk for particular diseases
- · Metrics for wellness—helping to efficiently optimize wellness for individual
- Healthcare 20% GNP; 86% healthcare dollars are spent on chronic disease
- · Scale of obesity, diabetes, etc.
- Over whole life—prevent Alzheimer's, diabetes, cardiovascular, etc
- Value of that data for discovery of improved healthcare and transformation of the healthcare industry. Many factors in calculus of \$s savings licios?

Strategic Partners in First Translational Pillars

- ISB—project design, analytics, develop better assays (cheaper and low volumes sample), analytics
- Providence—clinical expertise, patients, electronic medical records
- Arivale—execute dense, dynamics, personal data clouds, coaching, analytics
- MultiScale—extract patient records from clinical data base (Epic) and place in cloud queryable by Jupiter work stations



Novel Approach to Drug Discovery— Creation of Large Synthetic Natural Products Library—and High Throughput Screens

Mike Tyers-Montreal





The Idea



- Synthesize a billion synthetic natural products rapidly
- Screen a library of a billion natural products for selected drug targets rapidly







70 Self-Reported Diseases/Conditions are Currently Represented in the Arivale Research Platform (1200 pioneers)					
Allergy	32.2%	Type 2 diabetes	2.6%	Lupis	0.8%
High cholesterol	17.7%	Alcohol abuse	2.5%	Multiple sclerosis	0.8%
Arthritis/osteoarthritis	13.3%	Arthritis rheumatoid	2.5%	Gallbladder disease	0.7%
Gastroesophageal disease	13.0%	Gynecological other	2.4%	Epilepsy	0.7%
Hypertension	12.3%	Cancer other	2.3%		,.
Hypothyroidism	11.9%	Thyroid nodule	2.2%	Blood transfusion	0.7%
Sleep apnea	11.1%	Celiac disease	1.9%	Blood clot (leg)	0.7%
Migraine	9.0%	Concussion	1.8%	Grave's disease	0.6%
Depression	8.2%	Fibromyalgia	1.8%	Hepatitis A	0.6%
Skin eczema Asthma	7.9% 7.4%	Coronary artery disease Glaucoma	1.7%	Stomach ulcer	0.6%
Chicken pox	6.0%	Chronic fatigue syndrome	1.7%	Type 1 diabetes	0.5%
Irritable bowel syndrome	5.2%	PTSD	1.6%	Recent heart attack	0.5%
Fractures	5.1%	Kidney stones	1.6%		0.071
Bladder disease	5.0%	Hyperthyroidism	1.5%	Hip fracture	0.4%
Colon polyp	4.6%	Inflammatory bowel disease	1.5%	Stroke	0.4%
Osteoporosis	4.1%	Pneumonia	1.5%	Blood clot (lung)	0.3%
Skin abnormal moles	4.1%	Gout	1.4%	Emphysema	0.3%
Skin psoriasis	4.1%	Bipolar disease	1.4%	Hepatitis C	0.3%
Anemia	3.2%	Kidney disease	1.2%	Ovarian cancer	0.3%
Prostate enlargement	3.2%	Liver disease	1.1%		
Cataracts	3.1%	Gynecological endometriosis	1.1%	Prostate nodules	0.2%
Gynecological fibroids	2.9%	Lyme disease	0.9%	Hepatitis other	0.2%
Breast lump	2.8%	Prostate cancer	0.9%	Colon cancer	0.2%
Diverticulosis	2.6%	Breast cancer	0.8%	Hepatitis B	0.2%

